secwatch.observer — SEC 8-K summary
======================================

Issuer:     Editas Medicine, Inc. (EDIT)
CIK:        0001650664
Form:       8-K
Filed at:   2026-05-14T10:16:31+00:00
Accession:  0001650664-26-000049
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Editas reports EDIT-401 achieves ≥90% LDL-C reduction in NHPs; durable through 6 months
--------------------------------------------------------------------------------

- Single dose of EDIT-401 achieved ≥90% mean LDL-C reduction across all dose groups in non-human primates.
- Reduction durable through ~6 months; achieved with 10-40% functional editing of LDLR alleles and ≥6-fold hepatic LDLR protein increase.
- Promising preclinical safety profile: no adverse clinical observations at 1.5 mg/kg; undetectable oocyte delivery.
- Data in Ldlr loss-of-function mice suggest dose adjustments may not be needed for HeFH patients.
- Data support broader upregulation platform and continued advancement toward first-in-human clinical development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650664/000165066426000049/0001650664-26-000049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650664/000165066426000049/edit-20260514.htm
  HTML page:      https://secwatch.observer/filing/0001650664-26-000049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer